The GLP Journal
Research
Syntheses of the clinical trial evidence on weight loss, cardiovascular outcomes, and metabolic health.
Research
GLP-1s After Two Years: Staying On, Stepping Down, or Coming Off
STEP 5 held weight loss flat to 104 weeks. SURMOUNT-4 showed what stopping costs. And about half of people stop within a year anyway — what the long-term evidence actually supports.
10 min read · Updated Oct 10, 2026
Research
The GLP-1 Cost Index: What GLP-1s Actually Cost in 2026
A maintained, dated reference for GLP-1 pricing — insurance copays, brand list price, manufacturer cash-pay programs, compounded telehealth, and flat-price options — for semaglutide and tirzepatide.
8 min read · Updated Oct 5, 2026
Research
The 2026 GLP-1 Weight Loss Trial Landscape
A synthesis of the latest randomized controlled trials, real-world data, and the emerging evidence on muscle, metabolism, and maintenance.
14 min read · Updated Sep 15, 2026
Research
Do GLP-1s Lower Heart Attack Risk? What SELECT Proved
How GLP-1s became heart medicines: LEADER and SUSTAIN-6 in type 2 diabetes, then SELECT's first proof of cardiac benefit in people without diabetes — and what is still unproven.
11 min read · Updated Sep 29, 2026
Research
GLP-1s and Metabolic Syndrome: Beyond Weight
The emerging evidence on GLP-1s and metabolic syndrome, fatty liver, and the broader metabolic picture.
10 min read · Updated Sep 12, 2026